There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eagle Pharmaceuticals (EGRX) and Actinium Pharmaceuticals (ATNM) with bullish sentiments.
Eagle Pharmaceuticals (EGRX)
William Blair analyst Tim Lugo maintained a Buy rating on Eagle Pharmaceuticals yesterday. The company’s shares closed last Friday at $51.95.
According to TipRanks.com, Lugo is a 4-star analyst with an average return of 3.3% and a 37.1% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Collegium Pharmaceutical, and BioMarin Pharmaceutical.
Currently, the analyst consensus on Eagle Pharmaceuticals is a Moderate Buy with an average price target of $50.67.
See today’s analyst top recommended stocks >>
Actinium Pharmaceuticals (ATNM)
In a report released today, Matthew Cross from JonesTrading maintained a Buy rating on Actinium Pharmaceuticals, with a price target of $4.00. The company’s shares closed last Friday at $0.21.
According to TipRanks.com, Cross is a 3-star analyst with an average return of 1.9% and a 30.8% success rate. Cross covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences, Aldeyra Therapeutics, and Aptose Biosciences.
Actinium Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $2.75, implying an 1193.5% upside from current levels. In a report released today, Maxim Group also assigned a Buy rating to the stock with a $1.50 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
